Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 454-460

  Tanizaki, Yuko ^a   Kobayashi, Aya ^a   Shiro, Michihisa ^a   Ota, Nami ^a   Takano, Rei ^a   Mabuchi, Yasushi ^a   Yagi, Shigetaka ^a   Minami, Sawako ^a   Terada, Masaki ^b   Ino, Kazuhiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Wakayama Minami Radiology Clinic   (Japan)

Author keywords

FDG PET CT; Histological type; Ovarian borderline malignant tumor; Ovarian cancer

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER SURGERY; COLON CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GRANULOSA CELL TUMOR; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MAXIMUM STANDARDIZED UPTAKE VALUE; METASTASIS; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; OVARY CLEAR CELL ADENOCARCINOMA; OVARY ENDOMETRIOID ADENOCARCINOMA; OVARY MUCINOUS ADENOCARCINOMA; OVARY SEROUS ADENOCARCINOMA; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; STOMACH CANCER; TERATOMA; YOLK SAC TUMOR; ADENOCARCINOMA; CLINICAL TRIAL; DIAGNOSTIC USE; OVARY; OVARY TUMOR; PATHOLOGY; SCINTISCANNING;

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; OVARIAN NEOPLASMS; OVARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84900394868     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000074     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol. 2009;20:67-71.
3. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589-595.
4. Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET/ CT for primary ovarian cancerVa prospective study. Gynecol Oncol. 2007;105:145-149.
5. Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116:389-394.
6. Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011;32:549-553.
7. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol. 2010;194:311-321.
8. Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/CT in ovarian cancer. Ann Nucl Med. 2011;25:155-164.
9. Yoshida Y, Kurokawa T, Tsujikawa T, et al. Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET. J Ovarian Res. 2009;2:7-16.
10. Yamamoto Y, Oguri H, Yamada R, et al. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet. 2008;102:124-127.
11. Dodge JE, Covens AL, Lacchetti C, et al; Gynecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic reviewand meta-analysis. Gynecol Oncol. 2012;126:157-166.
12. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR Am J Roentgenol. 2010;194:W464-W470.
13. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
14. Risum S, Loft A, H?gdall C, et al. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Acta Oncol. 2011;50:415-419.
15. Nakamura K, Hongo A, Kodama J, et al. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama. 2012;66:53-60.
16. Chung HH, Kwon HW, Kang KW, et al. Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol. 2012;23:28-34.
17. Iagaru AH, Mittra ES, McDougall IR, et al. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun. 2008;29:1046-1051.
18. Bast RC Jr, Skates S, Lokshin A, et al. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012;22 (suppl 1):S5-S8.
19. Jung DC, Choi HJ, Ju W, et al. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer. 2008;18:637-641.
20. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
21. Hess V, A?Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
22. Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012;37:49-53.
23. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932.
24. Yasuda M, Miyazawa M, Fujita M, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep. 2008;19:111-116.
25. Tsukioka M, Matsumoto Y, Noriyuki M, et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep. 2007;18:361-367.
26. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653-658.
27. Berger KL, Nicholson SA, Dehdashti F, et al. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005-1008.
28. Kitajima K, Suzuki K, Senda M, et al. FDG PET/CT features of ovarian metastasis. Clin Radiol. 2011;66:264-268.
29. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266-271.
30. Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med. 2009;23:107-112.